Hanadie Yousef, PhD
Chief Executive Officer and Co-Founder
Dr. Hanadie Yousef is a leading expert on the biology of aging and mechanisms underlying tissue degeneration. A scientific pioneer with two decades experience in biomedical research, she is the co-founder and CEO of Juvena Therapeutics, a venture-backed biotechnology company mapping the therapeutic potential of secreted proteins to develop biologics that prevent, reverse and cure chronic and age-related diseases.
Dr. Yousef’s high-impact published research has been supported by fellowships and grants from the National Institute of Health (NIH), National Science Foundation (NSF), SPARK at Stanford, and the California Institute for Regenerative Medicine (CIRM) and led to multiple issued and pending patents. Under Dr. Yousef’s leadership, Juvena has secured nearly $50M since launching in 2018 and developed a proprietary pro-regenerative protein library supported by an artificial intelligence-enabled drug discovery and development platform.
The platform has enabled the identification, extensive preclinical validation, and lead optimization of three novel drug candidates, as well as discovery candidates for several chronic and age-related degenerative diseases.
Dr. Yousef earned her B.S. in Chemistry with a Spanish minor, summa cum laude from Carnegie Mellon University and a PhD in Molecular and Cell Biology from UC Berkeley as an NSF graduate research fellow. She pursued a 5-year postdoctoral fellowship in Neurology at Stanford School of Medicine as an NIH fellow and SPARK scholar. Her early research began at Regeneron and Genentech.
Learn more about Hanadie
Undergraduate Research and Achievements
Jeremy O’Connell, PhD
Chief Scientific Officer and Co-Founder
As Chief Scientific Officer and Co-Founder of Juvena Therapeutics, Dr. O’Connell oversees research strategy, pre-clinical science and manufacturing, and intellectual property efforts. Dr. O’Connell’s expertise in proteomics and systems biology expert accrued during a PhD from UT Austin, a postdoc at Harvard, and his time in industry.
Prior to Juvena Therapeutics, in his postdoctoral fellowship at Harvard Medical school in the lab of Steven Gygi, he leveraged large proteomics datasets to build machine learning classifiers to improve protein-protein interaction predictions within the ubiquitin system.
He has spearheaded research projects in multiple tier-one research institutions, including Harvard and Stanford, employing a combination of mass spectrometry, high throughput imaging, and computational approaches. His work has resulted in numerous peer-reviewed publications, approved and pending patents, millions in award grant funding as the primary PI, fellowships, and awards.
Learn more about Jeremy
Neil Berkley, MS, MBA
Chief Corporate Development Officer
Neil Berkley brings over 20 years of experience in corporate development, business development, and strategic planning from large pharma, midsize biotech/pharma and small biotech companies. He has completed a wide variety of transactions including in- and out-licensing transactions, M&A transactions, co-development/co-investment/co-commercialization transactions, research collaborations, financing transactions, device and supply agreements, etc. Neil has built and lead multiple business development, corporate development and alliance management teams.
Prior to joining Juvena, Neil was Chief Business Officer at AbCellera, a public biotech company focused on discovering novel antibody therapeutics. Previous to AbCellera, Neil was Vice President, Head of Business Development at Halozyme Therapeutics, a public biotechnology company focused on enabling platforms for the pharmaceutical industry. Neil has also held various business development and corporate development roles at Axerovision, COI (Avalon Incubator), Acadia, and GSK. Earlier in his career, Neil was Head of Business development at Cadence Pharmaceuticals, where he helped sell the company for $1.3B in cash. Neil also co-founded and helped build two San Diego-based biotechnology companies, Mpex Pharmaceuticals (acquired by Aptalis) and Vaxiion (a clinical stage bladder cancer company).
Neil holds a BS in molecular biology from the UC San Diego, as well as a Master of Science in cellular and molecular biology and an MBA from San Diego State University.
Learn more about Neil
Gayathri Swaminath, PhD, MBA
Senior Vice President of Discovery
Gayathri Swaminath, PhD, MBA brings over 17 years of preclinical, translational research & drug development experience in the pharmaceutical industry. Dr. Swaminath has strong drug discovery expertise in multiple therapeutic areas including diabetes, cardiovascular, fibrosis, inflammation, ophthalmology, oncology, immunology, pulmonary hypertension & renal diseases. Prior to joining Juvena Therapeutics, she served as Vice President for Research & Business Development at GreenfireBio, overseeing nonclinical & clinical development efforts for an oncology program, including fund raising & in-licensing activities. As a co-founder of MGFB Bio, she led the immuno-oncology preclinical activities for a cancer vaccine platform.
She was a Director in Cardiometabolic at Merck Research Laboratories, with previous leadership roles at Amgen. At Merck, & Amgen, she contributed to the preclinical pipeline in several therapeutic areas and advanced small molecules to the clinic, including Verquvo for heart failure. She has co-authored 35 publications in peer-reviewed journals, a book chapter, and holds several patents. As an invited speaker, she has presented at many national & international conferences. Dr. Swaminath completed her Ph.D. in Biochemistry from the University of Hyderabad, India, postdoctoral fellowship at Stanford University, and holds an MBA from Cornell University.
Learn more about Dr. Gayathri Swaminath
Mo (Mohammad) Tabrizi, PhD
Vice President of Preclinical and Nonclinical Development
Mo (Mohammad) Tabrizi, PhD brings over 25 years of experience in basic research, integrative pharmacology, translational sciences, and development of biologics. Prior to Joining Juvena Therapeutics, Dr. Tabrizi served in positions with increasing responsibilities at large companies such as Merck Research Laboratories, Medimmune (acquired by AstraZeneca), Abgenix (acquired by Amgen), and biotech companies such as Soteria Biotherapeutics and Acendis pharma. His product development experience spans many therapeutic areas including oncology, immune-oncology, and inflammatory diseases.
He has been an author or co-inventor on more than 50 original papers, reviews articles, published books and patents. Dr. Tabrizi has been an invited speaker to numerous national and international conferences. Dr. Tabrizi received his bachelor’s degree in Pharmacy from University of Houston (Summa Cum Laude) and his PhD from University at Buffalo, State University of New York (SUNY) in Pharmaceutical Sciences. He completed a postdoctoral training in Pharmacology at University of New York at Buffalo (SUNY) with a focus on therapeutics.
Learn more about Mohammad
Fengling Liu, PhD
Director of Protein Science
Dr. Fengling Liu brings over 10 years of industry experience developing multiple biologics. Since 2010 she served as the Protein Biochemistry lead or group lead of Protein Science in multiple biotechs in the bay area including Medimmune (AstraZeneca), Relypsa, Atreca and Arcus Biosciences.
Her protein science-focused research spanned target identification/confirmation, lead optimization, protein purification and engineering to support vaccine development, small molecule and antibody drug discovery in infectious disease and Immuno-Oncology. She was trained in Biochemistry and Structure Biology during her PhD at Georgia State University. She studied the molecular basis of HIV protease drug resistance through enzyme kinetics and X-ray crystal structures. She solved over a dozen super high resolution crystal structures of HIV/drug complexes and discovered a novel drug resistance mechanism.
During her postdoc in the lab of Professor Ted Jardetzky in the Structural Biology Department at Stanford Medical School, Dr. Liu studied human viral glycoprotein interactions to discover viral entry inhibitors.
Besides her passion for science and technology, Fengling also enjoys gardening and hiking with family and friends.
Learn more about Fengling
Eddie Moler, PhD
Vice President of Data Science
Eddie Moler brings over 20 years of experience leading pharmaceutical and clinical diagnostics R&D, data-science/algorithm/software intensive platform development, gene-target and biomarker discovery and validation, establishing and scaling high-performing data-science & software teams, and collaboration management.
Previously, Eddie led Quest Diagnostics’ Bioinformatics organization, leading the development and launch of dozens of advanced clinical genomic diagnostic tests while more than quadrupling the size of the team across multiple sites. He has led clinical/biological research projects and the development of production-scale clinical and research platforms at Quest Diagnostics, GE Healthcare, Tethys Bioscience, Novartis, and the US Department of Energy.
Dr. Moler has published over 50 peer-reviewed papers including clinical and molecular medicine, population health, and health economics, and has 7 issued patents on clinical risk algorithms, biomarkers, automated histopathology image analysis, drug targets, and discovery technology. Eddie received a PhD in Chemistry from UC Berkeley and a BS in Chemistry from Texas A&M University.
Learn more about Eddie
Thach Mai, PhD
Principal Scientist, Drug Discovery & Platform Development
Dr. Thach Mai joined Juvena Therapeutics as a Stem Cell Biologist and Bioinformatician to lead the validation and discovery of the key rejuvenating protein factors in Juvena Therapeutics’ complex embryonic secretome cocktail and develop and improve Juvena’s HTS platform for protein therapeutic discovery.
Dr. Mai is a trained stem cell biologist and immunologist with a focus on the mechanisms of muscle degeneration and aging. Dr. Mai received his PhD in Molecular Biology and Immunology from UC Irvine and a postdoctoral fellowship at Stanford University. During his fellowship, Dr. Mai used bioinformatics to accurately quantify high-throughput genomics data from multi-nucleated cells (heterokaryons) consisting of human and mouse gene transcripts to discover a novel transcription factor that drives the reprogramming of fibroblasts to pluripotency. Self-taught in ML with a strong passion for rapid biological discovery, he has generated deep learning models that identify muscle-specific aging genotypes as well as a machine learning classifier for the myogenic differentiation state of a single cell with a heterogeneous population.
Dr. Mai has been awarded multiple fellowships including from the National Institute of Health (F32), has three, 1st author publications including in Nature Journals, and is co-author of thirteen publications with one in review.
Learn more about Thach
Clarence Dunn, PHD
Principal Scientist, Drug Discovery
Clay Dunn joined Juvena Therapeutics as a Principal Scientist on the in vitro drug discovery team. Clay received a MPH degree in epidemiology from George Washington University where he worked with Andrew Friedman at the Genetic Epidemiology Branch, NCI, on a study characterizing the clinical features of von Hippel Lindau disease. He received his Ph.D. from the University of Washington, where he was trained in epithelial cell biology in the lab of William Carter, Ph.D.. He focused on studying the elements of outside→in signaling mechanisms in both activated and quiescent keratinocyte cell populations.
Clay completed his post-doctoral training in the lab of Paul Lampe, Ph.D. at the Fred Hutchinson Cancer Research Center (FHCRC) in Seattle, WA.. In the Lampe Lab, Clay investigated the biology connecting connexin proteins and Gap Junctional Intercellular Communication (GJIC) to several key cellular functions. His focus was on the kinases and pathways that regulate gap junction function during epidermal wounding and cardiac ischemia.
Clay has spent nearly 10 years in the Bay Area biotech industry developing assays and complex cellular models to support pre-clinical drug development. In five years at Amgen, Clay leveraged high throughput imaging and analysis to conduct IND-enabling studies supporting the development of several assets in Amgen’s pipeline. At Encoded Therapeutics, Clay worked to develop novel bioanalytical assays for the company’s gene therapies, which aim to treat pediatric epileptic seizure syndromes.
Learn more about Clarence
Yasaman Heidarian joined Juvena Therapeutics as a Scientist working on disease modeling and drug discovery. Yasaman completed her undergraduate and Master’s work on signaling pathways in ovarian cancer at the University of Tehran. She then joined the Cancer Research Center of Iran where she worked on the role of oxytocin signaling pathway in breast cancer. Yasaman did her Ph.D. studies at Indiana University, where she studied metabolic regulations during animal development and disease.
Yasaman has years of experience working on oncology research, stem cell biology and differentiation, genome engineering, and disease modeling. Prior to Juvena Therapeutics, Yasaman worked as Research Co-op at Black Diamond Therapeutics and as a Scientist at Inscripta focusing on drug discovery and genome engineering respectively.
Learn more about Yasaman
Jyoti Ahlawat, PHD
Dr. Ahlawat joined Juvena Therapeutics as an Associate Scientist: Drug Discovery. She holds a Master’s degree in Biotechnology from the Indian Institute of Technology, Roorkee (IITR), and a Ph.D. in Chemistry from the University of Texas at El Paso (UTEP). She is a recipient of Academic and Research Excellence award from the College of Science (UTEP). Her dissertation research involved developing materials and testing them in-vitro to develop therapeutics against the gravest of human diseases such as Alzheimer’s (AD) and Parkinson’s disease (PD).
Dr. Ahlawat has published more than 18 articles and book chapters in international, peer-reviewed, reputed journals. She is a recipient of the title “Rising Star in Nanoscience and Nanotechnology” at the 10th IEE International Conference on nanomaterials and applications (IEEE-NAP 2020). She has won Best presentation awards at the Equniox (2022), 26th Annual BioEnvironmental Polymer Society (BEPS-2019), Graduate Expo (2018), and 8th International conference on smart materials, structure, and systems (ISSS-2017). In addition, she has won various travel awards (2018-2020), four research awards (2019-2021), and graduate scholarships (2019-2020). She is an Editorial board member of the Journal Future Trends in Nanotechnology and is serving as a Guest Editor for Science Progress (SAGE Journal).
She has served as Vice president of Graduate Student Assembly (2018), and as President of BioChem graduate student chapter (2021). She recently received honorarium from Society for Science for serving as a Science Talent Search Evaluator in 2021. She received Certificate of Appreciation from the Graduate School for her contribution to Undergraduate Learning in 2021. She has served as science judge for the Sun Country Science & Engineering fair (2021), Regeneron International Science & Engineering fair (2021) and at 2nd annual El Paso STEM expo competition (2019). She worked as an intern for eight months with a medical device company where she participated and led international projects which included renewal and registration of ophthalmic lenses in Mexico, Creating Instructions for Use (IFUs) and technical files, and Translation of IFUs into European languages.
Dr. Ahlawat serves as a peer-reviewer for journals such as Cell Biochemistry and Biophysics, Nanotechnology for Environmental Engineering, Environmental Science, Journal for Drug Delivery, and technology, and Phytotherapy. She delivered four invited scientific talks at International Conferences in 2021-2022.
Learn more about Jyoti
Senior Program Manager
Andy joined Juvena as a senior manager of portfolio & product management. Within this role he will lead the planning and integration of Juvena’s development, discovery, and core product. Andy joins us with over 10 years of combined biotechnology experience in research, development, and program management. Most recently Andy has worked within research, development, and portfolio management at Kite Pharma, Freenome, and Catalent.
Andy holds a Bachelor’s in Biochemical Engineering from Ohio University, an MBA from the University of Southern Indiana, is a trained project manager who holds a PMP from the PMI, holds a post graduate certification in clinical trial management / design from the University of California San Diego, and a post graduate certificate in Bioinformatics from Harvard.
In his free time Andy enjoys programming, studying, running, hiking, traveling, reading and his dogs.
Learn more about Andy
Principal Machine Learning Engineer
Since joining Juvena Therapeutics, Tejaswini Ganapathi has worked on the development of AI models that power Juvena’s protein discovery for targeted in vitro screening, and will be exploring the application of AI to other aspects of the company’s drug pipeline as well.
Tejaswini has extensive experience in machine learning algorithm development both in research and production and towards building end to end ML systems. Her industry experience spans various domains such as healthcare, medical imaging, finance and wireless networks. She has been an early employee at 2 startups with successful exits and holds ~10 patents. She pursued her graduate studies at University of Toronto and University of Texas at Austin, both specializing in machine learning.
Outside of AI and work, Tejaswini is a RYT200 Yoga instructor, is trained in Indian Classical music and tries to contribute her time to animal rescues.
Learn more about Tejaswini
Scientist, In vitro Human Disease Modeling
- Experienced and motivated Scientist with a strong background in stem cell biology, human embryonic stem cell, cell culture, molecular biology, vector construction and analytical techniques, including qPCR, ELISA ,FACS, ICC, and Western blot
- 25+ years proficiency in human embryonic stem cell culture and directed differentiation
- Generating Cardiomyocytes, retinal Hepatocytes and Endothelial Progenitor Cells, from human embryonic stem cells to high purity and success rate.
- Developing models of end-stage liver disease and liver cirrhosis in primary human hepatocytes (PHH) and primary rodent hepatocytes, including 2D and 3D spheroids and co-cultures with myofibroblasts, stellate cells and Kupffer cells.
- Design and execution of high-throughput in vitro plasmid-based miRNA screening for acquired liver disease targets.
- Evaluated the transduction efficiency and long term transgene expression of AAV1 and Adeno virus in endothelial cells
- Generation of iPS cells with different methods (e.g. mRNA, lenti virus, sendai virus, siRNA reprogramming)
- Identified optimal cell condition for Exosome production, purification and characterization
- Developed ELISA assay kit for Exosome quantification
- Experience with molecular biology techniques and protein isolation
- Excellent technical, organizational, and communication skills
- Strong analytical and problem-solving capabilities
- Ability to work both independently and in a team environment
Learn more about Mohammad
Rohit Jadhav, PHD
Dr. Rohit Jadhav brings more than 12 years of cross disciplinary experience encompassing the fields of oncology, immune aging and auto-immune diseases. He has extensive experience in algorithm development for diagnostic and prognostic biomarker discovery dealing with diverse datasets investigating the Transcriptome, Epigenome and DNA mutations in clinical cohorts.
Dr. Jadhav earned his B.Tech. in Bioinformatics from India, a M.S. in Bioinformatics from Indiana University, Indianapolis, a PhD in Molecular Medicine from UT Health, San Antonio as a CPRIT pre-doctoral fellow, followed by a postdoctoral fellowship in Immunology at Stanford School of Medicine and Mayo Clinic.
Masters & PhD (2009-2016)
Dr. Jadhav worked on identifying epigenetic biomarkers investigating alterations in DNA methylation across different cancer types including breast, ovarian, endometrial, oral and prostate. He was awarded a Cancer Prevention and Research Institute of Texas (CPRIT) Predoctoral Fellowship, which enabled him to be involved in collaborative projects focusing on non-invasive approaches for biomarker discovery. One such project involved use of single-cell RNA sequencing to study circulating tumor cells and another involved studying DNA methylation in cell free DNA, both from peripheral blood. As a lead bioinformatician for these studies, he implemented classification-based prediction methods to enable identification of a panel of biomarkers to be used in determining treatment approaches for prostate cancer patients belonging to different subtypes. These studies have led to 3 approved patents from his mentor Dr. Tim Huang. During this time, Dr. Jadhav was also a lead author on the study that identified DNA methylation biomarkers capable of identifying predisposition to breast cancer after prenatal exposure to the compound bisphenol A and preventive effects of genistein.
Postdoctoral Fellowship (2017-2022)
Dr. Jadhav’s work at Stanford University and Mayo Clinic with Dr. Jorg Goronzy who is a leading expert in immune aging and auto-immunity, focused on epigenetics in the context of chromatin accessibility and specifically alterations in the immune cell types like CD4 and CD8 T cells during aging and autoimmune diseases like rheumatoid arthritis. He was also a lead author studying epigenetic alterations in exhausted T-cells post checkpoint blockade therapies in collaboration with Dr. Rafi Ahmed from Emory University. During this time Dr. Jadhav built pipelines deployed in on-prem clusters and in the cloud for analyzing and visualizing data from RNA-seq, ATAC-seq, TCR-seq, single cell multiome (RNA+ATAC), single cell Cite-seq (RNA+Protein) among others.
Dr. Jadhav has published over 30 peer-reviewed papers with over a thousand citations.
Learn more about Rohit
Senior Research Associate
Ashil joined Juvena Therapeutics as a Research Associate to contribute to pre-clinical in-vivo research, including the functional and behavioral validation of lead protein therapeutics developed by the in-vitro team.
Ashil obtained his bachelor’s degree in biology from the University of California, Riverside. Working in the Nabity Lab, he focused on genetics with the aim to parse out an endosymbiont genome from that of its host, the woolly apple aphid, to elucidate the mechanisms the endosymbiont utilized to fortify the amino-acid poor diet of the aphid.
Realizing his aptitude for dissection and surgery, he began a two-year stint at the Oka Lab at Caltech post-graduating. After beginning by managing and genotyping mouse colonies of up to 55 lines and 400+ animals for the lab, he moved towards behavioral testing and survival intracranial surgery. He worked as a co-author on a project to create an opiate-biosensor, validating in-vitro and ex-vivo results in-vivo by both optimizing and executing intracranial viral injections, and optic fiber implantation in the VTA in the brain. This in conjunction with post-op fiber photometry and DeepLabCut analysis allowed visualization of how the brain processes mu opiates such as fentanyl.
In Ashil’s free time, he is a basketball fanatic, both in playing pickup and following the pros!
Learn more about Ashil
Md Khadem Ali
Dr. Ali joined Juvena Therapeutics as a Pharmacology Scientist to lead the in vivo studies for the adipose and pulmonary research programs. He is an accomplished lung biologist with 10 years of a strong background in inflammatory, allergic, respiratory, pulmonary vascular, and infectious diseases. His overarching goal is to discover improved therapies for individuals with lung and metabolic diseases.
Dr. Ali’s academic training and research experience across 4 nations and 3 continents have provided him with an excellent background in multiple biological disciplines, including immunology, molecular biology, microbiology, and cell biology. He received a B. Sc in Biotechnology and Genetic Engineering from Khulna University, Bangladesh, an M.Sc. in Systems Biotechnology from Chung-Ang University, South Korea, and a Ph.D. in Immunology and Microbiology from the University of Newcastle, Australia. His Ph.D. focused on investigating how iron, infection, and immunity affect one another in the context of lung diseases, including asthma, COPD, and IPF. These studies showed that increased iron in the lung is associated with small airway fibrosis, inflammation, and reduced lung function in systemic iron-overloaded mouse models. Targeting with an iron chelator drug prevented airway fibrosis and lung function reduction in a mouse model of IPF, highlighting the potential for a novel therapeutic approach to this disease. Having shown iron overload in clinical asthma, he used two mouse models of systemic iron overload and showed that this was associated with inflammation, increased mucus secretion, and scarring in the airways. Subsequent studies demonstrated that the combined treatment with the iron chelator deferoxamine and antibiotic tobramycin reversed lung dysfunction in mice infected with Pseudomonas aeruginosa. As a postdoctoral fellow at Stanford, he investigated ways to enhance bone morphogenic protein 2 (BMPR2), a gene that is haploinsufficient or reduced in expression and function in PAH, a disease of lung blood vessel dysfunction. RNAseq, siRNA-mediated high throughput screening, and in vitro and in vivo models led to the identification of two proteins, PTP1b and ELK3 as modifiers of BMPR2 signaling. In addition, his research discovered two long non-coding RNAs LINC02593 and RGMB-AS1, that modulate BMPR2 signaling and pulmonary vascular remodeling. A second project focused on hemorrhagic telangiectasia (HHT), a related disease associated with mutations in ALK1, ENG, and SMAD4. He identified a small molecule drug that activates BMPR2 signaling and inhibits VEGF signaling pathways, two critical pathways in HHT.
To date, he has published 36 peer-reviewed high-impact publications, 12 as first author and 9 as a second author (average IF >10, with 800+ citations), 23 conference abstracts, 13 conference presentations, 2 book chapters, 1 patent, and 2 funded research grants. His research was also selected for oral and poster presentations at international/national conferences. Recognizing his contributions, he received seven academic and research awards. He mentored 5 undergraduates, 1 junior Ph.D. student, demonstrated immunology and microbiology lab course for 3 years, and 1 high school summer student. He took on a leadership role as a co-Director of the Stanford Cardiovascular Institute Postdoc conference 2020. In addition, he has been regularly invited to conduct peer reviews for elite journals in the pulmonary medicine field.
Beyond academic, professional life, he enjoys traveling, playing, and watching cricket, watching movies.
Learn more about Khadem
Hee Ju Kim, MS
Hee Ju joined Juvena Therapeutics as a Research Associate to work on the validation of our pipeline of pro-regenerative lead protein therapeutic candidates in in vivo preclinical models of aging and degenerative diseases caused by aging.
She is originally from Korea and she received her master’s degree in biochemistry from Korea University. Her master’s degree was supported by Brain Korea 21 (BK21). During her masters, she was trained in basic molecular techniques and in vitro experiments. Her master’s thesis was about double stranded DNA repair in yeast ribosomal protein S3.
Before joining Juvena Therapeutics, Hee Ju was trained as a research volunteer in the Peter W. Laird lab, Norris Cancer Center at the University of Southern California (USC). She was involved in the epigenomic projects and she designed the reaction oligo for Mouse MetyLight and some of the primers, which she designed, were published in the paper, Urology.
Hee Ju started improving her in vivo skills in the David J. Anderson’s lab as a research assistant for 5 years at the California Institute of Technology (Caltech). She was involved in the projects of anxiety and aggression. After she moved to Austin, she worked with Michael R. Drew as a research associate for 4 years at the Center for Learning and Memory, UT Austin. Then she worked at the KPC lab in Korea for 2 years in preclinical models of neurodegeneration, in particular Alzheimer’s Disease and Parkinson’s Disease.
In Hee Ju’s free time, she enjoys traveling with family, playing golf, and spending time with her lovely dog Kelly.
Learn more about Hee Ju
Zhihua Li, PhD
Principal Protein Engineer
Dr. Li is a biologist with a multidisciplinary background in Biochemistry, Immunology, Cell and Molecular Biology, with 7 years of research experience in academia and 4 years in industry. He joined Juvena Therapeutics as a Protein Engineering Scientist to build protein expression and purification pipelines and to improve Juvena Therapeutics’ pipeline library of rejuvenating proteins for therapeutic purposes.
Following a BS in Biochemistry and Master’s Degree (MS) in genetics from scientific and technical universities in China, and a second MS in Molecular Microbiology and Immunology from the University of Southern California all during which he conducted research, Dr. Li completed his PhD (2007) and postdoctoral training (2014) in Cell and Molecular Biology from UT Austin, where he studied protein-protein interactions in different ways: first by combining computational predictions with experimental validations to discover 15 new protein factors functioning in the biogenesis of ribosomes; then by combining powerful mass spectrometry with protein fractionation techniques to create protein complex maps for both yeast and human cells. Continuing his exploration of novel protein interactions in his postdoctoral research, Dr. Li elucidated the self-cleavage mechanism of a novel membrane-bound transcription factor that drives oligodendrocyte differentiation. He’s published multiple co-authorships and first authorship studies along the way.
Before joining Juvena, Dr. Li worked in industry and biotech startups as Lead Scientist, Life Science Consultant, Scientific Advisor and R&D director. As Lead Scientist at BMLogic, Dr. Li developed and optimized the protein secretory production system in Pichia, leading to improved protein secretion efficiency and greatly reduced protein degradation.
Besides his passion for science, he enjoys spending time with his kid and exploring nature.
Learn more about Zhihua
Research Associate II
Ben graduated from UC Davis with bachelor’s degree in biochemistry and molecular biology. While at UC Davis, he worked in Dr. Keith Baar’s lab, and was part of several research projects relating to skeletal muscle metabolism and the effects of nutrition and aging on skeletal muscle, and became responsible for performing transfections of both primary and immortal cell lines for various projects going on in the lab. Additionally, Ben worked as a biochemistry intern at Marrone Bio Innovations in Davis where he gained experience with performing and developing high throughput assays, as well as both small and large scale purification of native and recombinant proteins from several prokaryotic species.
Learn more about Benjamin
Biotech Operations Manager
Jamie Romero has over 14 years of biotech industry experience, starting as a Research Associate and growing into a Biotech Operations Manager. She brings to Juvena years of experience within the biotech industry, from her earlier days of working at the bench to managing biotech operations in scaling companies. Jamie has significant experience across facilities operations, office management, HR, accounting, and more. Jamie Romero’s career has fed her need to learn through the field of biomedical research while experiencing the excitement of the biotech start-up world. Jamie earned her Bachelors of Science in molecular biology and minor in Chemistry from SJSU.
Jamie is detail oriented, an effective multi-tasker and used to fast-paced, changing and uncertain environments. Having the ability to prioritize in deadline driven environments, Jamie excels when challenged, wearing multiple hats. She learned by dedicating 12 years to Omniox, Inc., where she was the first employee and grew with the company, taking on multiple diverse tasks to support their growth and needs, followed by Catalyst Biosciences. Many exciting opportunities opened up for her as she had the great opportunity to grow and learn in many different roles, being the “go-to” person; point-of-contact for, if, and, when anything came up through most if not all departments of the company – from lab to office, from finance to HR, from coordinating team-building and company events to providing EA support for the CEO and Executive team.
So, when Jamie came across the opportunity to join Juvena, an early, scaling biopharma start-up tackling some of the greatest unmet needs of our time through an exciting biologics discovery and development platform, a mission Jamie whole-heartedly believes in, she excitedly jumped to the challenge and can’t wait to see what the future with the company entails.
Learn more about Jamie
Senior Research Associate
Han joined Juvena Therapeutics as a Research Associate to contribute to Dr. Li’s research on protein expression, purification pipelines, and to improve Juvena Therapeutics’ pipeline library of rejuvenating proteins for therapeutic purposes.
Han obtained his bachelor’s degree in biochemistry from the University of San Diego, with research areas focusing on exploring the enzymatic interactions of malate dehydrogenases and the utilization of defect-formations in the synthesis of metal-organic frameworks.
Before joining Juvena, Han worked as a Scientist III at the startup NovoNutrients for 4 years. He was heavily involved with the upstream and downstream process of gas fermentation using proprietary bioreactors and consortias. In addition to the fermentation work, he developed a novel synthetic biology platform to express high-value biomolecules ranging from enzymes, pharmaceuticals, to carotenoids in various consortia species. Later on, he took on the role of a strain engineer to develop a quick and reliable method to generate genomically-integrated strains of bacteria for industrial processes.
In Han’s free time, he enjoys playing the piano, hiking, and cycling around the Bay Area.
Learn more about Han
Munir Yousef, MS
Munir Yousef joined Juvena Therapeutics as a bioinformatics analyst to contribute to Juvena’s growing platform by developing robust data analysis pipelines for their in silico protein drug discovery platform. After realizing his passion for data-driven discovery of solutions to real world problems, Munir obtained his Masters degree in Applied Data Science from Syracuse University.
Before officially joining the team, Munir worked as a data science consultant and helped develop internal data analysis and visualization tools to support Juvena’s growing R&D platforms.
Learn more about Munir
Senior Research Associate
Sarah joined Juvena Therapeutics as a Senior Research Associate to contribute to Dr. Fengling Liu’s research on protein expression and purification. She obtained her bachelor’s degree in molecular and cell biology from the University of California, Berkeley.
Before joining Juvena Therapeutics, Sarah worked as a Research Associate in the antibody discovery field, where she attained hybridoma sequences, antibody transient expression, and hit identification. Prior to transitioning to research, Sarah worked in the clinical diagnostics field as a Lab Administrative Manager. She managed lab operations while staying active on the bench.
In Sarah’s free time, she enjoys creating content for her cat’s social media, gaming with friends, and attending ballet performances.
Learn more about Sarah